Genetic Subtypes, Pretreatment Drug Resistance, and Associated Factors Among Individuals Newly Diagnosed With HIV-1 in Zhejiang Province From 2022 to 2024: Cross-Sectional Study
JMIR Public Health and Surveillance · 2026-09-17 · 12 · e96139-e96139
DOI: 10.2196/96139 ↗At a glance
Querschnittstudie in JMIR Public Health and Surveillance, published online on 2026-09-17. Written by Wei Cheng and 8 co-authors. Institution: Zhejiang Provincial Center for Disease Control and Prevention, 3399 Binsheng Road, Binjiang District, Hangzhou, Zhejiang, Hangzhou, 310051, China, 86…. Major MEDLINE topics: HIV-1, HIV Infections, Drug Resistance, Viral. 31 references. The full text is freely available in PubMed Central.
Abstract (original language)
Background
Pretreatment drug resistance (PDR) poses an increasing threat to the effectiveness of antiretroviral therapy and treatment-as-prevention strategies. Zhejiang Province, an economically developed region in eastern China with high population mobility, experiences complex HIV-1 subtype dynamics and evolving resistance patterns. However, recent population-based evidence integrating HIV genetic subtypes, PDR prevalence, and associated factors remains limited.
Objective
This study aimed to characterize HIV-1 subtype distribution, estimate the prevalence of PDR, and identify associated demographic, virological, and prophylaxis-related factors among newly diagnosed individuals in Zhejiang Province from 2022 to 2024.
Methods
We conducted a cross-sectional study among adults newly diagnosed with HIV-1 in Zhejiang Province between 2022 and 2024. Demographic, epidemiological, laboratory, and exposure prophylaxis information was collected through the provincial HIV surveillance system. Partial Pol gene sequences were amplified and sequenced to determine HIV subtypes and drug resistance mutations. PDR was interpreted using the Stanford University HIV Drug Resistance Database. Logistic regression models were applied to identify factors associated with PDR.
Results
Among 8798 newly diagnosed individuals, the predominant subtypes were CRF07_BC (n=3913, 44.5%), CRF01_AE (n=2524, 28.7%), and CRF08_BC (n=954, 10.8%), with significant heterogeneity across age groups, sexes, transmission routes, and diagnosis years ( P
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Zhejiang Provincial Center for Disease Control and Prevention, 3399 Binsheng Road, Binjiang District, Hangzhou, Zhejiang, Hangzhou, 310051, China, 86 057187115191.
Cite
APA
Cheng, W., Fan, Q., Zhang, J., Jiang, J., Yang, J., Xu, Y., Chen, L., Chai, C., & Pan, X. (2026). Genetic Subtypes, Pretreatment Drug Resistance, and Associated Factors Among Individuals Newly Diagnosed With HIV-1 in Zhejiang Province From 2022 to 2024: Cross-Sectional Study. JMIR Public Health and Surveillance, 12, e96139-e96139. https://doi.org/10.2196/96139
Vancouver
Cheng W, Fan Q, Zhang J, Jiang J, Yang J, Xu Y, et al. Genetic Subtypes, Pretreatment Drug Resistance, and Associated Factors Among Individuals Newly Diagnosed With HIV-1 in Zhejiang Province From 2022 to 2024: Cross-Sectional Study. JMIR Public Health and Surveillance. 2026;12:e96139-e96139. doi:10.2196/96139
BibTeX
@article{Cheng2026,
author = {Cheng, Wei and Fan, Qin and Zhang, Jiafeng and Jiang, Jun and Yang, Jiezhe and Xu, Yun and Chen, Lin and Chai, Chengliang and Pan, Xiaohong},
title = {Genetic Subtypes, Pretreatment Drug Resistance, and Associated Factors Among Individuals Newly Diagnosed With HIV-1 in Zhejiang Province From 2022 to 2024: Cross-Sectional Study},
journal = {JMIR Public Health and Surveillance},
year = {2026},
volume = {12},
pages = {e96139--e96139},
doi = {10.2196/96139}
}
EUVIMED